Optometrists in Lincoln, ME Accepting Medicare
3 Optometrists found. Showing 1 - 3
 Mark B Weatherbee, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 26 Enfield Rd, Lincoln, ME 04457 Phone: 207-794-2020 Fax: 207-794-8288 |
Gregory Michael Farrell, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 53 Transalpine Rd, Lincoln, ME 04457 Phone: 207-538-3700 Fax: 207-528-2880 |
 Mark B Weatherbee Od Optometrist Medicare: Medicare Enrolled Practice Location: 26 Enfield Road, Lincoln, ME 04457 Phone: 207-794-2020 Fax: 207-794-2020 |
News Archive
Meridian Bioscience announces fiscal 2009 fourth-quarter and full-year financial results
Net sales for the fourth quarter of fiscal 2009 were $42,461,000 as compared to $36,475,000 for the same period of the prior fiscal year, an increase of 16%. Net earnings for the fourth quarter of fiscal 2009 were $8,930,000, or $ 0.22 per diluted share, up 16% over the fourth quarter of fiscal 2008.
FDA accepts Insys NDA for Fentanyl SL Spray to treat breakthrough cancer pain
Insys Therapeutics, Inc. today announced that the Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Fentanyl SL Spray. The FDA will notify Insys of its PDUFA date in the 74-day letter which is expected in the upcoming weeks.
Researchers discover chronic stress accelerates breast cancer progression
Chronic stress acts as a sort of fertilizer that feeds breast cancer progression, significantly accelerating the spread of disease in animal models, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.
Bortezomib reduces inflammation and promotes bone healing in arthritis models
A new study by Greek researchers suggests that the biologic drug bortezomib (Velcade), a proteasome inhibitor used to treat multiple myeloma (bone marrow cancer), may represent a promising treatment for rheumatoid arthritis (RA). In this study, bortezomib displayed favorable effects in an animal model of inflammatory arthritis that mimics RA, in reducing disease severity and inflammation, and promoting bone healing. Full findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).
Adcare Health Systems prices underwritten public offering of Series A Preferred Stock
AdCare Health Systems, Inc. the "Company") announced today that it has priced a "best efforts" underwritten public offering of its 10.875% Series A Cumulative Redeemable Preferred Stock (the "Series A Preferred Stock") at a public offering price of $25.00 per share.
› Verified 2 days ago
Occupational Therapists
Physical Therapists
Podiatrists
Speech-Language Pathologists
Optometrists